ArticleClinicoEconomics and outcomes research : CEOR2018

An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in Switzerland.

Richard F Pollock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.